Dispatches from BPI Europe 2016

Roche: Bispecific and complex mAbs driving process development

By Dan Stanton contact

- Last updated on GMT

Roche: Bispecific and complex mAbs driving process development

Related tags: Bispecific antibodies, Monoclonal antibodies

The increasing complexity of biopharmaceuticals is driving process development innovation according to Swiss drug firm Roche.

The methods used to make blockbuster monoclonal antibodies like Herceptin and Avastin are not sufficient to produce next generation biopharmaceuticals according to Wolfgang Kuhne, Roche’s VP of technical development bioprocessing.

He told delegates at the Bioprocess International European Summit in Vienna, Austria that making candidates like ACE910 – a bispecific antibody granted breakthrough designation for haemophilia last September​ – had required a considerable process development effort.

“There are no more classical standard approaches and we have to make a huge effort for our bioprocessing development,”​ he said.

Downstream challenges

The initial stages of making bispecific antibodies are very similar to those used to make ‘simpler’ drugs like Herceptin.

The molecules are produced in bioreactors by cultured Chinese Hamster Ovary (CHO) cells.

The challenge, Kuhne continued, had been the development of purification processes capable of harvesting the innovative molecules.

Established technologies like Protein-A based resins had not proved effective he said, adding that processes like virus removal are also more complex for bispecific antibodies than for mAbs.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Related suppliers

Follow us

Products

View more

Webinars